Cargando…

SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy

OBJECTIVE: The purpose was to provide uptake and radiation dose estimates to salivary glands (SG) and pathologic lesions following radioiodine therapy (RIT) of differentiated thyroid cancer patients (DTC). METHODS: A group of DTC patients (n = 25) undergoing (131)I therapy joined this study with var...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuqbeitah, Mohammad, Demir, Mustafa, Sağer, Sağit, Asa, Sertaç, Işıkcı, Nazenin Ipek, Sönmezoğlu, Kerim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817440/
https://www.ncbi.nlm.nih.gov/pubmed/36628262
http://dx.doi.org/10.1007/s12553-022-00718-y
_version_ 1784864754814156800
author Abuqbeitah, Mohammad
Demir, Mustafa
Sağer, Sağit
Asa, Sertaç
Işıkcı, Nazenin Ipek
Sönmezoğlu, Kerim
author_facet Abuqbeitah, Mohammad
Demir, Mustafa
Sağer, Sağit
Asa, Sertaç
Işıkcı, Nazenin Ipek
Sönmezoğlu, Kerim
author_sort Abuqbeitah, Mohammad
collection PubMed
description OBJECTIVE: The purpose was to provide uptake and radiation dose estimates to salivary glands (SG) and pathologic lesions following radioiodine therapy (RIT) of differentiated thyroid cancer patients (DTC). METHODS: A group of DTC patients (n = 25) undergoing (131)I therapy joined this study with varying amounts of therapeutic activity. Sequential SPECT/CT scans were acquired at 4 ± 2, 24 ± 2, and 168 ± 3 h following administration of 3497–9250 MBq 131I. An earlier experiment with Acrylic glass body phantom (PET Phantom NEMA 2012 / IEC 2008) was conducted for system calibration including scatter, partial volume effect and count loss correction. Dose calculation was made via IDAC-Dose 2.1 code. RESULTS: The absorbed dose to parotid glands was 0.04–0.97 Gy/GBq (median: 0.26 Gy/GBq). The median absorbed dose to submandibular glands was 0.14 Gy/GBq (0.05 to 0.56 Gy/GBq). The absorbed dose to thyroid residues was from 0.55 to 399.5 Gy/GBq (median: 21.8 Gy/GBq), and that to distal lesions ranged from 0.78 to 28.0 Gy/GBq (median: 3.12 Gy/GBq). 41% of the thyroid residues received dose > 80 Gy, 18% between 70–80 Gy, 18% between 40–70 Gy, and 23% has dose < 40 Gy. In contrast, 18% of the metastases exhibited a dose > 80 Gy, 9% between 40–60 Gy, and the dose to the vast majority of lesions (64%) was < 40 Gy. CONCLUSION: It was inferred that dose estimation after RIT with SPECT/CT is feasible to apply, together with good agreement with published (124)I PET/CT dose estimates. A broad and sub-effective dose range was estimated for thyroid residues and distal lesions. Moreover, the current methodology might be useful for establishing a dose–effect relationship and radiation-induced salivary glands damage after RIT.
format Online
Article
Text
id pubmed-9817440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98174402023-01-06 SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy Abuqbeitah, Mohammad Demir, Mustafa Sağer, Sağit Asa, Sertaç Işıkcı, Nazenin Ipek Sönmezoğlu, Kerim Health Technol (Berl) Original Paper OBJECTIVE: The purpose was to provide uptake and radiation dose estimates to salivary glands (SG) and pathologic lesions following radioiodine therapy (RIT) of differentiated thyroid cancer patients (DTC). METHODS: A group of DTC patients (n = 25) undergoing (131)I therapy joined this study with varying amounts of therapeutic activity. Sequential SPECT/CT scans were acquired at 4 ± 2, 24 ± 2, and 168 ± 3 h following administration of 3497–9250 MBq 131I. An earlier experiment with Acrylic glass body phantom (PET Phantom NEMA 2012 / IEC 2008) was conducted for system calibration including scatter, partial volume effect and count loss correction. Dose calculation was made via IDAC-Dose 2.1 code. RESULTS: The absorbed dose to parotid glands was 0.04–0.97 Gy/GBq (median: 0.26 Gy/GBq). The median absorbed dose to submandibular glands was 0.14 Gy/GBq (0.05 to 0.56 Gy/GBq). The absorbed dose to thyroid residues was from 0.55 to 399.5 Gy/GBq (median: 21.8 Gy/GBq), and that to distal lesions ranged from 0.78 to 28.0 Gy/GBq (median: 3.12 Gy/GBq). 41% of the thyroid residues received dose > 80 Gy, 18% between 70–80 Gy, 18% between 40–70 Gy, and 23% has dose < 40 Gy. In contrast, 18% of the metastases exhibited a dose > 80 Gy, 9% between 40–60 Gy, and the dose to the vast majority of lesions (64%) was < 40 Gy. CONCLUSION: It was inferred that dose estimation after RIT with SPECT/CT is feasible to apply, together with good agreement with published (124)I PET/CT dose estimates. A broad and sub-effective dose range was estimated for thyroid residues and distal lesions. Moreover, the current methodology might be useful for establishing a dose–effect relationship and radiation-induced salivary glands damage after RIT. Springer Berlin Heidelberg 2023-01-06 2023 /pmc/articles/PMC9817440/ /pubmed/36628262 http://dx.doi.org/10.1007/s12553-022-00718-y Text en © The Author(s) under exclusive licence to International Union for Physical and Engineering Sciences in Medicine (IUPESM) 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Abuqbeitah, Mohammad
Demir, Mustafa
Sağer, Sağit
Asa, Sertaç
Işıkcı, Nazenin Ipek
Sönmezoğlu, Kerim
SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title_full SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title_fullStr SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title_full_unstemmed SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title_short SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
title_sort spect/ct-based dosimetry of salivary glands and iodine-avid lesions following (131)i therapy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817440/
https://www.ncbi.nlm.nih.gov/pubmed/36628262
http://dx.doi.org/10.1007/s12553-022-00718-y
work_keys_str_mv AT abuqbeitahmohammad spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy
AT demirmustafa spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy
AT sagersagit spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy
AT asasertac spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy
AT isıkcınazeninipek spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy
AT sonmezoglukerim spectctbaseddosimetryofsalivaryglandsandiodineavidlesionsfollowing131itherapy